Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Vaccine|February 11, 2014
Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled studyRoman Chlibek, Jan Smetana, Karlis Pauksens, et al.
International Journal of Medical Microbiology : IJMM|January 8, 2025
Prevalence of Borrelia burgdorferi sensu lato infection in the Czech RepublicRoman Chlibek, Jan Smetana, Kateřina Kybicová, et al.
Biomed Research International|July 3, 2014
Genome-wide screening of cytogenetic abnormalities in multiple myeloma patients using array-CGH technique: a Czech multicenter experienceJan Smetana, Jan Frohlich, Romana Zaoralova, et al.
Klinicka Mikrobiologie a Infekcni Lekarstvi|July 25, 2016
[Biological factors influencing infectious diseases transmitted by invasive species of mosquitoes]Vanda Boštíková, Markéta Pasdiorová, Jan Marek, et al.
Human Vaccines & Immunotherapeutics|February 21, 2018
Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adultsTino F Schwarz, Stephanie Volpe, Gregory Catteau, et al.
European Journal of Haematology|May 10, 2016
Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significanceAneta Mikulasova, Jan Smetana, Marketa Wayhelova, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 17, 2009
Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapyPavel Nemec, Zuzana Zemanova, Henrieta Greslikova, et al.
Haematologica|May 28, 2017
The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myelomaAneta Mikulasova, Christopher P Wardell, Alexander Murison, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 8, 2013
Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomibJan Smetana, Kristina Berankova, Romana Zaoralova, et al.
Human Vaccines & Immunotherapeutics|June 20, 2019
Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trialsLidia Oostvogels, Thomas C Heineman, Robert W Johnson, et al.
Pageof 5